Skip to main content
. 2016 Sep 29;21(3):456–466. doi: 10.1111/jcmm.12989

Figure 2.

Figure 2

Copy‐number variations (CNV) in BCNP1 are frequent in human cancer. Cross‐cancer alteration summary for BCNP1 from 59 studies. The tumours analysed are: ovarian serous cyst adenocarcinoma (OSC), adenoid cystic carcinoma (ACyC), uterine corpus endometrial carcinoma (UCEC), breast cancer (BRC) (patient xenograft), sarcoma, adrenocortical carcinoma (ACC), cancer cell line encyclopedia (CCLE), breast invasive carcinoma (BIC), brain lower grade glioma (BGM), oesophageal carcinoma (EAC), liver hepatocellular carcinoma (LHC), lung squamous cell carcinoma (LSC), bladder cancer (BC), skin cutaneous melanoma (SCM), colorectal adenocarcinoma (CAC), head and neck squamous cell carcinoma (HNC), stomach adenocarcinoma (SC), cervical squamous cell carcinoma (CSC), prostate adenocarcinoma (PRAD), acute myeloid leukemia (AML), lung adenocarcinoma (LC), pancreatic adenocarcinoma (PAC) and thyroid carcinoma (TC). The data were obtained and analysed using cBioPortal. The amplifications and deletions were represented as red and blue bars, respectively. (A) CNV alterations of BCNP1 in the TCGA data sets for each cancer study. (B) Histogram illustrating the percentage of BCNP1 alterations for cancer studies combined according to cancer type.